Scientist, entrepreneur, and investor—three small words to describe the way Hatch BioFund Managing Partner Dr. Lorenzo Pellegrini has devoted his career to translating the cutting-edge into impactful solutions. From founding six biotech companies to driving investments in industry-shaping firms like Elevation Pharmaceuticals and Anacor, Lorenzo has consistently championed the necessity of fusion between innovation and practicality in the life sciences. In this episode of Fractals: Life Science Conversations, Lorenzo and host Colin Miller take a wide-ranging deep dive on:

• The rapid evolution of biotech within the last few decades, from small molecules to biologics, and its impact on drug evolution, supply, demand, and adaptation.
• Balancing financial success with societal impact in life sciences venture capital decisions—and why 80% of these decisions hinge not upon the science, but on the management team executing it.
• The role of fractional support in scaling startups and avoiding costly over-hiring mistakes.
• The importance of exploring global markets beyond the US to diversify pricing and reimbursement strategies.

Tune in to Fractals on your preferred podcast platform, and contact Bracken to learn more about how we can support biotech companies in navigating complex M&A decisions.